DALLAS, Sept. 27 /PRNewswire-FirstCall/ -- HemoBioTech, Inc. (OTC
Bulletin Board: HMBT) announced today that Dr. Arthur P. Bollon, Chairman &
CEO of HemoBioTech will make a presentation at the NanoTX '06 conference on
September 27-28, 2006 in Dallas, Texas. He will address the quest for a
substitute for human blood and present key features of HemoTech(TM), the
novel blood substitute under development by HemoBioTech.
Ross Perot will be the keynote speaker at the conference, which will
also include His Royal Highness The Duke of York. The conference will
involve over 150 nanotechnology specialists from 30 different countries and
a special session involving six Nobel Laureates from various disciplines.
"We are very excited about being asked to speak at this prestigious
conference," said Dr. Arthur P. Bollon, Chairman and CEO of HemoBioTech.
"This will be an excellent opportunity to share our novel approach to the
quest for a blood substitute which is employed in HemoTech(TM)."
About HemoBioTech, Inc.
HemoBioTech is engaged in the commercial development of HemoTech(TM), a
novel human blood substitute technology exclusively licensed from Texas
Tech University Health Sciences Center. HemoTech(TM) is chemically modified
bovine hemoglobin, which not only carries oxygen in the blood, but can also
induce erythropoiesis (red blood cell production). The hemoglobin is
modified with ATP, adenosine and GSH. The Company believes that
HemoTech(TM) may possess properties that diminish the intrinsic toxicities
which have plagued other attempts at developing blood substitutes, based
upon pre-clinical and initial human clinical trials undertaken outside the
U.S. by prior holders of this technology. HemoTech(TM) is being subjected
to further studies and testing to confirm and possibly expand on these
results. HemoTech(TM) is being developed to help reduce or eliminate the
danger resulting from acute blood loss in trauma, as well as for other
conditions. Corporate headquarters are located at J. P. Morgan
International Plaza, 14221 Dallas Parkway, Suite 1400, Dallas, Texas 75254.
The Company website is http://www.hemobiotech.com . For further information
contact Dr. Arthur Bollon at 214-540-8411 or email@example.com .
Safe Harbor Statement
Except for historical information, the matters discussed in this news
release may be considered "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. Such statements include
declarations regarding the intent, belief or current expectations of
HemoBioTech and its management and are valid only as of today, and we
disclaim any obligation to update this information. These statements are
subject to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the statements
made. Factors that might cause such a difference include, among others the
successful pre- clinical development, the successful completion of clinical
trials, the FDA review process and other governmental regulation,
pharmaceutical collaborator interest and ability to successfully develop
and commercialize drug candidates, competition from other pharmaceutical
companies, product pricing and third party reimbursement, and other factors
which are included in HemoBioTech's Annual Report on Form 10-KSB for the
year ended December 31, 2005, as amended, and HemoBioTech's other reports
filed with the Securities and Exchange Commission.
SOURCE HemoBioTech, Inc.